Skip to Content


In the US, Nimodipine (nimodipine systemic) is a member of the drug class calcium channel blocking agents and is used to treat Ischemic Stroke, Migraine Prevention and Subarachnoid Hemorrhage.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Categories

Calcium channel blocker

Cerebral vasodilator

Treatment of cerebrovascular disorders

Chemical Name

3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimetyl-4-(3-nitrophenyl)-, 2-metoxyetyl 1-metyletyl ester

Foreign Names

  • Nimodipinum (Latin)
  • Nimodipin (German)
  • Nimodipine (French)
  • Nimodipino (Spanish)

Generic Names

  • Nimodipina (OS: DCIT)
  • Nimodipine (OS: DCF, USAN, BAN)
  • Bay e 9736 (IS: Bayer)
  • NMDP (IS)
  • Nimodipin (PH: Ph. Eur. 8)
  • Nimodipine (PH: BP 2016, Ph. Eur. 8, USP 38)
  • Nimodipinum (PH: Ph. Eur. 8)

Brand Names


BANBritish Approved Name
DCFDénomination Commune Française
DCITDenominazione Comune Italiana
ISInofficial Synonym
OSOfficial Synonym
PHPharmacopoeia Name
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.